Shanghai Junshi Biosciences Co Ltd Asset Resilience Ratio

Latest as of December 2025: 4.85%

Shanghai Junshi Biosciences Co Ltd asset resilience ratio. Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Shanghai Junshi Biosciences Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥600.81 Million
≈ $87.92 Million USD Cash + Short-term Investments

Total Assets

CN¥12.38 Billion
≈ $1.81 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Shanghai Junshi Biosciences Co Ltd (2014–2025)

Asset resilience ratio of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Junshi Biosciences Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688180 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥600.81 Million 4.85%
Total Liquid Assets CN¥600.81 Million 4.85%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Shanghai Junshi Biosciences Co Ltd Asset Resilience Ratio by Year (2014–2025)

Shanghai Junshi Biosciences Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.85% CN¥600.81 Million
≈ $87.92 Million
CN¥12.38 Billion
≈ $1.81 Billion
+0.87pp
2024-12-31 3.99% CN¥430.51 Million
≈ $63.00 Million
CN¥10.80 Billion
≈ $1.58 Billion
+3.99pp
2020-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥8.01 Billion
≈ $1.17 Billion
0.00pp
2019-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥4.42 Billion
≈ $647.14 Million
-0.13pp
2018-12-31 0.13% CN¥5.52 Million
≈ $807.16K
CN¥4.26 Billion
≈ $622.98 Million
-11.96pp
2017-12-31 12.09% CN¥147.43 Million
≈ $21.57 Million
CN¥1.22 Billion
≈ $178.48 Million
-20.42pp
2016-12-31 32.50% CN¥373.47 Million
≈ $54.65 Million
CN¥1.15 Billion
≈ $168.14 Million
-38.21pp
2014-12-31 70.71% CN¥235.44 Million
≈ $34.45 Million
CN¥332.94 Million
≈ $48.72 Million
--
pp = percentage points

About Shanghai Junshi Biosciences Co Ltd

SHG:688180 China Biotechnology
Market Cap
$3.24 Billion
CN¥22.17 Billion CNY
Market Cap Rank
#4520 Global
#655 in China
Share Price
CN¥28.96
Change (1 day)
-2.95%
52-Week Range
CN¥28.93 - CN¥45.04
All Time High
CN¥151.00
About

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more